A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.

Jeffrey C Powell James B Meiling Michael S Cartwright

Published in: Muscle & nerve (2023)

These results suggest that most patients are satisfied when switching from nusinersen to risdiplam, with the method of delivery being a primary factor.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
healthcare
primary care
prognostic factors
patient reported outcomes